What Are Experts Saying About The Trial?
Dr David Planchard- Prof at University Paris Sacly- Head of Thiracic Cancer Group/Gustave Roussy write in linkdin
Congrats #JulienMazieres on the great presentation and the encouraging results for our lung NETs. Really impressive study testing the combination in all the different neuroendocrine tumor subtypes! #SCLC #ELCC2026
Key Takeaway
The trial demonstrates that obrixtamig plus ezabenlimab shows manageable safety and encouraging efficacy in DLL3-positive SCLC, particularly at higher dose levels.
This approach highlights the potential of DLL3-targeted immunotherapy combined with checkpoint inhibition as a next-generation strategy in small cell lung cancer.
You can read full abstract here
